MX2016001301A - Metodo para tratar la miocardiopatia hipertrofica. - Google Patents

Metodo para tratar la miocardiopatia hipertrofica.

Info

Publication number
MX2016001301A
MX2016001301A MX2016001301A MX2016001301A MX2016001301A MX 2016001301 A MX2016001301 A MX 2016001301A MX 2016001301 A MX2016001301 A MX 2016001301A MX 2016001301 A MX2016001301 A MX 2016001301A MX 2016001301 A MX2016001301 A MX 2016001301A
Authority
MX
Mexico
Prior art keywords
hypertrophic cardiomyopathy
treating hypertrophic
formula
treating
cardiomyopathy
Prior art date
Application number
MX2016001301A
Other languages
English (en)
Inventor
Luiz Belardinelli
Ramin Farzaneh-Far
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2016001301A publication Critical patent/MX2016001301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

La presente divulgación se refiere a un compuesto de fórmula (I) o fórmula (II) o una sal farmacéuticamente aceptable deI mismo, para uso en el tratamiento de la miocardiopatía hipertrófica.
MX2016001301A 2013-08-01 2014-07-28 Metodo para tratar la miocardiopatia hipertrofica. MX2016001301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361861359P 2013-08-01 2013-08-01
PCT/US2014/048495 WO2015017351A1 (en) 2013-08-01 2014-07-28 Method of treating hypertrophic cardiomyopathy

Publications (1)

Publication Number Publication Date
MX2016001301A true MX2016001301A (es) 2016-04-07

Family

ID=51352822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001301A MX2016001301A (es) 2013-08-01 2014-07-28 Metodo para tratar la miocardiopatia hipertrofica.

Country Status (13)

Country Link
US (1) US9125916B2 (es)
EP (1) EP3027189A1 (es)
JP (1) JP2016525575A (es)
KR (1) KR20160035060A (es)
CN (1) CN105473143A (es)
AU (1) AU2014296477A1 (es)
CA (1) CA2919669A1 (es)
EA (1) EA201690214A1 (es)
HK (1) HK1222571A1 (es)
MX (1) MX2016001301A (es)
NZ (1) NZ715554A (es)
SG (1) SG11201600102SA (es)
WO (1) WO2015017351A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170007617A1 (en) * 2015-07-09 2017-01-12 Gilead Sciences Drive Intravenous formulations of a late sodium current inhibitor
WO2018048977A1 (en) * 2016-09-08 2018-03-15 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxazepin compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201837023A (zh) * 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2013112932A1 (en) * 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Also Published As

Publication number Publication date
EP3027189A1 (en) 2016-06-08
HK1222571A1 (zh) 2017-07-07
CA2919669A1 (en) 2015-02-05
US20150038487A1 (en) 2015-02-05
NZ715554A (en) 2017-01-27
CN105473143A (zh) 2016-04-06
JP2016525575A (ja) 2016-08-25
AU2014296477A1 (en) 2016-01-28
SG11201600102SA (en) 2016-02-26
US9125916B2 (en) 2015-09-08
KR20160035060A (ko) 2016-03-30
WO2015017351A1 (en) 2015-02-05
EA201690214A1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2015009209A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
SG10201804034QA (en) Methods for treating hypotension
MX2013000009A (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo.
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX357763B (es) Tratamiento para cancer pancreatico.
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
EA201491581A1 (ru) Везикулярные композиции
MX2018001684A (es) Metodo de curacion de heridas.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX358470B (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
MX2015012610A (es) Pacritinib deuterizado.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
IN2013CH04519A (es)
UA80533U (uk) (s)-(+)-n,n-диметил-3-(1-нафтален-1-ілокси)-1-фенілпропан-1-амін та його фармацевтично прийнятні солі